Human iPSC Line (Episomal, PBMC)
| Catalog# | Unit | Unit Price (USD) | Actions |
|---|---|---|---|
| iPS15 | 5x105 cells/vial | $1,558.00 | Add to Cart |
Highlights:
Footprint-free human iPS15 cell lines generated by episomal plasmids are ideally suited for various research purpose including 1) differentiating various somatic cells or organoid models for phenotypic and target-based compound screening, 2) establishing genetically modified disease model through CRISPR/Cas9 editing, and 3) generating functional cells/tissues as regenerative biology initiatives. iPS15 has several features such as:
- Low passage and long-term viability
- Off the shelf - simple thaw the cells and plate them onto serum-free, feeder-free culture
- Transgene- and Virus-free (episomal)
- Homogeneity– Originated from a single iPSC clone
Description:
Footprint-free human iPS (induced pluripotent stem) cell line was derived from human peripheral blood mononuclear cells (PBMCs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using episomal plasmids.
Specifications:
| Product Name | Human iPSC Line (Episomal, PBMC) |
|---|---|
| Shipping Condition |
Dry Ice - Overnight Shipping |
| Storage and Stability |
Store in vapor phase of liquid nitrogen immediately upon receipt. This product is stable for 6 months when stored as directed. |
| Quality Control | Human iPS cells were grown in feeder free conditions with mTeSR1 medium. Each lot of human iPS cells is tested for growth and viability following recovery from cryopreservation. In addition, each lot is tested for expression of TRA-1-60 and Oct4, as well as the activity of alkaline phosphatase. |
| Restricted Use |
For Research Use Only. Not for use in diagnostic or therapeutic procedures. |
Single-cell transcriptomics reveals multiple neuronal cell types in human midbrain-specific organoids bioRxiv (2019)
- Clinical Applications of Induced Pluripotent Stem Cells – Stato Attuale Cell Biology and Translational Medicine (2018)
- Pseudotyping exosomes for enhanced protein delivery in mammalian cells International Journal of Nanomedicine (2017)
- (Patent) Engineered Exosomes for the Delivery of Bioactive Cargo Using Transmembrane VSV-G United States Patent Application 20190015333A1 (2019)